1-2 of 2
Anders G. Holst
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Visit-to-Visit Variability of Hemoglobin A1c in People Without Diabetes and Risk of Major Adverse Cardiovascular Events and All-Cause Mortality

Jonas Ghouse, Morten W. Skov, Jørgen K. Kanters, Bent Lind, Jonas L. Isaksen, Paul Blanche, Stig Haunsø, Lars Køber, Jesper H. Svendsen, Morten S. Olesen, Anders G. Holst, Thomas A. Gerds, Jonas B. Nielsen
Journal: Diabetes Care
Diabetes Care 2019;42(1):134–141
DOI: https://doi.org/10.2337/dc18-1396
Published: 23 October 2018
View article titled, Visit-to-Visit Variability of Hemoglobin A<sub>1c</sub> in People Without Diabetes and Risk of Major Adverse Cardiovascular Events and All-Cause Mortality
Open the PDF for Visit-to-Visit Variability of Hemoglobin A<sub>1c</sub> in People Without Diabetes and Risk of Major Adverse Cardiovascular Events and All-Cause Mortality in another window
Includes: Supplementary data
Journal Articles

Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial

Andrew J. Ahmann, Matthew Capehorn, Guillaume Charpentier, Francesco Dotta, Elena Henkel, Ildiko Lingvay, Anders G. Holst, Miriam P. Annett, Vanita R. Aroda
Journal: Diabetes Care
Diabetes Care 2018;41(2):258–266
DOI: https://doi.org/10.2337/dc17-0417
Published: 15 December 2017
View article titled, Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial
Open the PDF for Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial in another window
Includes: Supplementary data